Scientific article
Open access

The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE

Published inThrombosis research, vol. 203, p. 155-162
Publication date2021-07
First online date2021-05-15

Introduction: Clinical characteristics and outcomes of venous thromboembolism (VTE) patients with concomitant anemia are unclear. This study compares baseline characteristics, treatment patterns, and 24-month outcomes in patients with and without anemia within GARFIELD-VTE.

Materials and methods: GARFIELD-VTE (ClinicalTrials.gov: NCT02155491) is a global, prospective, non-interventional registry of real-world treatment practices. Of the 10,679 patients enrolled in GARFIELD-VTE, 7698 were eligible for analysis. Primary outcomes were all-cause mortality, recurrent VTE, and major bleeding in VTE patients with or without concomitant anemia over 24-months after diagnosis. Event rates and 95% confidence intervals were estimated using Poisson regression. Adjusted hazard ratios were calculated using Cox proportional hazard models.

Results: Distribution of VTE events in 2771 patients with anemia and 4927 without anemia was similar (deep-vein thrombosis alone: 61·1% vs. 55·9%, pulmonary embolism ± deep vein thrombosis: 38·9% vs. 44·0%, respectively). Patients with anemia were older (62.6 year vs. 58.9 years) than those without. At baseline, VTE risk factors that were more common in patients with anemia included hospitalization (22·0% vs. 6·8%), surgery (19·2% vs. 8·2%), cancer (20·1% vs. 5·6%) and acute medical illness (8·3% vs. 4·2%). Patients with anemia were more likely to receive parenteral anticoagulation therapy alone than those without anemia (26·6% vs. 11·7%) and less likely to receive a direct oral anticoagulant (38·5% vs. 53·5%). During 24-months of follow-up, patients with anemia had a higher risk (adjusted hazard ratio [95% confidence interval]) of all-cause mortality (1·84 [1·56-2·18]), major bleeding (2·83 [2·14-3·75]). Among anemia patients, the risk of all-cause mortality and major bleeding remained higher in patients with severe anemia than in those with mild/moderate anemia, all-cause mortality: HR 1·43 [95% CI: 1·21-1·77]; major bleeding: HR 2·08 [95% CI: 1·52-2·86]).

Conclusions: VTE patients with concomitant anemia have a higher risk of adverse clinical outcomes compared with those without anemia. Further optimization of anticoagulation therapy for VTE patients with anemia is warranted.

  • Anemia
  • Anticoagulation
  • Deep vein thrombosis
  • Pulmonary embolism
  • Venous thromboembolism
  • Anemia / complications
  • Anticoagulants / therapeutic use
  • Humans
  • Prospective Studies
  • Pulmonary Embolism
  • Venous Thromboembolism / complications
Citation (ISO format)
GOTO, Shinya et al. The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. In: Thrombosis research, 2021, vol. 203, p. 155–162. doi: 10.1016/j.thromres.2021.05.007
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal0049-3848

Technical informations

Creation03/23/2022 11:51:00 AM
First validation03/23/2022 11:51:00 AM
Update time03/16/2023 6:50:27 AM
Status update03/16/2023 6:50:25 AM
Last indexation02/01/2024 8:24:25 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack